Melatonin-Loaded Sacchachitin Nanofiber Hydrogel for Atopic Dermatitis: Technical Insights and Translational Value

Study Background and Research Question

Atopic dermatitis (AD) is a widespread, chronic inflammatory skin disorder that poses persistent therapeutic challenges, affecting up to 20% of children and 3% of adults globally. Its multifactorial etiology—encompassing genetic mutations (notably in filaggrin), environmental triggers, immune dysregulation, and microbiome disturbances—leads to disrupted skin barrier function and heightened susceptibility to comorbidities such as asthma and allergic rhinitis. Conventional management relies heavily on topical corticosteroids and calcineurin inhibitors, which, while effective, are constrained by adverse effects including skin atrophy and immunosuppression with long-term use. Biologicals and JAK/PDE4 inhibitors have expanded options but remain costly and are not universally suitable, particularly for pediatric or mild cases. This landscape highlights the pressing need for safe, non-steroidal, and accessible alternatives capable of both restoring the skin barrier and modulating local immune responses.

Key Innovation from the Reference Study

The reference study by Lin et al. (International Journal of Nanomedicine, 2026) presents a novel topical platform: a hydrogel composed of sacchachitin nanofibers (SCNF) loaded with melatonin. The innovation lies in leveraging SCNF's biocompatibility and structural properties as a scaffold, while utilizing melatonin's immunomodulatory and anti-inflammatory activities to address AD pathogenesis without relying on steroids or calcineurin inhibitors. Notably, the formulation is designed for stability and mechanical integrity, essential for practical dermatological application.

Methods and Experimental Design Insights

The investigators developed a hydrogel matrix using sacchachitin nanofibers, incorporating melatonin to form the melatonin-loaded SCNF hydrogel (MSC). Physicochemical characterization addressed stability, adhesive and mechanical properties, and melatonin release kinetics. To evaluate therapeutic efficacy, a 2,4-dinitrochlorobenzene (DNCB)-induced atopic dermatitis model in NC/Nga mice was employed—a well-established system recapitulating key human AD features such as epidermal hyperplasia, immune cell infiltration, and Th2-skewed responses. Clinical severity scoring, histopathological analysis, and immunological assessments (IgE, IgG1, IL-4) provided multidimensional outcome measures. Stability of melatonin within the hydrogel was longitudinally assessed over 31 days.

Protocol Parameters

• Hydrogel preparation: Sacchachitin nanofibers hydrated and mixed with melatonin at defined concentrations to achieve uniform dispersion.
• Animal model induction: DNCB sensitization and challenge protocol in NC/Nga mice to reliably induce AD-like dermatitis.
• Topical application: Melatonin-loaded hydrogel applied to lesional skin daily, with comparison arms including blank hydrogel and untreated controls.
• Biomarker assessment: Serum IgE, IgG1, and tissue IL-4 levels measured post-intervention to quantify immunomodulatory effects.
• Stability testing: Melatonin content and hydrogel integrity monitored at intervals up to 31 days.

Core Findings and Why They Matter

The melatonin-loaded SCNF hydrogel demonstrated pronounced therapeutic benefits in the preclinical AD model. Specifically, the formulation:

• Significantly reduced clinical AD severity scores compared to both blank hydrogel and untreated groups.
• Attenuated epidermal hyperplasia and mast cell infiltration, indicating effective suppression of both structural and immune-driven pathology.
• Lowered Th2-associated immunological markers, including serum IgE, IgG1, and tissue IL-4 levels, reflecting a shift away from the pathogenic allergic response characteristic of AD (see reference).
• Preserved melatonin stability and hydrogel mechanical properties for at least 31 days, supporting its feasibility for extended topical use.

These findings collectively suggest that the synergistic platform—using SCNF as a stable, biocompatible carrier and melatonin as the active modulator—can achieve both barrier reinforcement and immunological normalization without the risks inherent to steroidal agents.

Comparison with Existing Internal Articles

While the reference study focuses on dermatological application, there are conceptual parallels with precision protease inhibition strategies discussed in internal resources. For example, the article "Precision Protease Inhibition for Translational Impact" addresses the challenge of protein preservation during cellular stress responses—a concern mirrored in the need to maintain protein integrity during tissue extraction and biomarker analysis in dermatological studies. Similarly, "Protease Inhibitor Cocktail EDTA-Free: Enhancing Protein..." highlights the importance of using EDTA-free formulations for workflows involving phosphorylation-sensitive proteins, which is also relevant for downstream analysis of cytokines and signaling intermediates in skin disease research. These internal articles emphasize the role of advanced protease inhibition in supporting reproducible, high-fidelity protein analysis, a requirement that complements the rigorous biomarker quantification in the present study.

Limitations and Transferability

Despite promising preclinical data, several limitations warrant consideration. First, the efficacy and safety of the melatonin-loaded SCNF hydrogel have not yet been demonstrated in human subjects; thus, translational gaps remain. The DNCB-induced mouse model, while informative, does not fully recapitulate the complexity of human AD pathogenesis or chronicity. Additionally, long-term effects, potential for sensitization, and batch-to-batch reproducibility of the hydrogel formulation require further investigation. The study's focus on Th2 biomarkers provides mechanistic insight, but broader immunophenotyping—including Th1/Th17 responses—may be necessary for comprehensive immune profiling. Finally, scalability and cost-effectiveness of SCNF production for clinical deployment are undetermined.

Research Support Resources

For researchers aiming to replicate or extend upon this work, rigorous preservation of protein integrity during sample collection and analysis is vital, particularly for immunological and signaling studies in skin disease models. The Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) (SKU K1010) can be integrated into protein extraction protocols to prevent proteolytic degradation without introducing EDTA, thus supporting workflows such as Western blotting, co-immunoprecipitation, and phosphorylation analysis that are sensitive to divalent cations. This approach, as discussed in related internal resources, helps ensure the reliability of downstream immunological and mechanistic studies in translational dermatology and beyond.